However, it would be helpful if future studies aim to distinguish AD symptomology (mere presence of mild cognitive impairment) and AD pathology (Aβ accumulation) while applying the AT(N) classification system [Aβ (A), tau (T), and neurodegeneration (N)] which will afford more direct assessments of neuropathologic changes. This evidence concerns the gene MAPT and Cognitive impairment.